Search Results for "Blue Oval Pill With 68 Taro"

09:20 EST 18th January 2017 | BioPortfolio

Matching Channels

Blue hues

Von Willebrand's Disease

von Willebrand disease (vWD) is the most common hereditary coagulation abnormality described in humans, although it can also be acquired as a result of other medical conditions. It arises from a qua...

Matching News

Better Sleep in the ICU: Blue Pill or Red Pill... or No Pill?

What is the best way to improve sleep in the ICU? Does pharmacologically induced sleep offer more benefit than sedation--or should we be focusing on promoting a non-drug approach? Anesthesiology

Taro Announces Appointment of New CEO and New Board Member Nominations

HAWTHORNE, N.Y.–(BUSINESS WIRE)–Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) announced today the appointment of Mr. Uday Baldota as Ch...

Taro Announces Sale of U.S. Rights to Keveyis® to Strongbridge Biopharma plc

Taro Pharmaceutical Industries Ltd.Mariano Balaguer, (914) 345-9001VP, Chief Financial OfficerMariano.Balaguer@taro.comorWilliam J. Coote, (914) Read ...

Taro Appoints New Chief Financial Officer

HAWTHORNE, N.Y.–(BUSINESS WIRE)–Taro Pharmaceutical Industries Ltd. (NYSE:TARO) (“Taro” or the “Company”) today announced the appointment of Mariano Balaguer as Vic...

Taro Provides Results for September 30, 2016

Tuesday, November 8th 2016 at 10:32pm UTC HAWTHORNE, N.Y.–(BUSINESS WIRE)– Taro Pharmaceutical Industries Ltd. (NYSE:TARO) (“Taro” or the “Company”) today provided unaudited financ...

Vanda settles Fanapt patent litigation with Taro

David SalazarVanda and Taro have entered a license agreement delineating when Taro's generic of Vanda's Fanapt can enter the market.  read more

Taro Pharmaceutical Industries' (TARO) CEO, Kal Sundaram on Q2 2017 Results - Earnings Call Transcript

TARO SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Taro Pharmaceutical Industries Ltd. – TARO

NEW ORLEANS–(BUSINESS WIRE)–$TARO #TARO–Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investo...

Matching PubMed Articles

Better Sleep in the Intensive Care Unit: Blue Pill or Red Pill… or No Pill?

Two-step identification of taro (Colocasia esculenta cv. Xinmaoyu) using specific psbE-petL and simple sequence repeat-sequence characterized amplified regions (SSR-SCAR) markers.

Colocasia esculenta cv. Xinmaoyu is an eddoe-type taro cultivar local to Taicang, Jiangsu Province, China; it is characterized by its pure flavor, glutinous texture, and high nutritional value. Due to...

Genetic Diversification and Dispersal of Taro (Colocasia esculenta (L.) Schott).

Taro (Colocasia esculenta (L.) Schott) is widely distributed in tropical and sub-tropical areas. However, its origin, diversification and dispersal remain unclear. While taro genetic diversity has bee...

Additivity of Nebivolol/Valsartan Single-Pill Combination Versus Other Single-Pill Combinations for Hypertension.

Effects of the Chinese herbal formula "Zuojin Pill" on the pharmacokinetics of dextromethorphan in healthy Chinese volunteers with CYP2D6*10 genotype.

Zuojin Pill has been shown to inhibit the cytochrome P450 (CYP) 2D6 isoenzyme in vitro. In Chinese individuals, CYP 2D6*10 is the most common allele with reduced enzyme activity. In this study, we inv...

Search Whole site using Google

Quick Search
Advertisement Advertisement